Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma
dc.contributor.author | Filho, Adhemar Longatto | en_US |
dc.contributor.author | Baltazar, Fátima | en_US |
dc.contributor.author | Bedrossian, Carlos W.M. | en_US |
dc.contributor.author | Michael, Claire W. | en_US |
dc.contributor.author | Schmitt, Fernando C. | en_US |
dc.date.accessioned | 2007-12-04T18:38:59Z | |
dc.date.available | 2009-01-07T20:01:16Z | en_US |
dc.date.issued | 2007-12 | en_US |
dc.identifier.citation | Filho, Adhemar Longatto; Baltazar, FÁtima; Bedrossian, Carlos; Michael, Claire; Schmitt, Fernando C. (2007). "Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma." Diagnostic Cytopathology 35(12): 786-791. <http://hdl.handle.net/2027.42/57412> | en_US |
dc.identifier.issn | 8755-1039 | en_US |
dc.identifier.issn | 1097-0339 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/57412 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18008346&dopt=citation | en_US |
dc.description.abstract | Homogeneity of mesothelial and lymphatic endothelial cells, express some markers that are presumed to be exclusive of the endothelium was recently reported. This similarity is important to improve the diagnosis and prognosis of malignant mesothelioma (MM). Additionally, some of these markers provide the rationale for specific molecular-targeted novel therapies aimed at MM, an aggressive malignant neoplasm, with an usually dismal prognosis. The goal of our study was to determine the prevalence and expression pattern of VEGF receptor-3 (VEGFR-3) immunoreactivity in MM and whether this immunoreactivity occurs in different phenotypes of this neoplasm. Formalin-fixed and paraffin-embedded samples from 29 MM cases and 5 metastatic carcinomas were immuno-stained for VEGFR-3 according to the streptavidin–biotin–peroxidase complex technique using a primary antibody (Zymed Laboratories, CA, USA) diluted at 1:200. Lymphatic vessels (LV) were outlined mainly in the peripheral area surrounding the neoplasms. Blood vessels were only rarely positive for VEGFR-3 in a pattern easily distinguishable from LV. In 25 out of 29 cases (86.2%) LV were strongly positive for VEGFR-3: 14 cases (48.2%) exhibited positive VEGFR-3 reactivity in malignant cells. Epitheliod MM showed a moderate to intense VEGFR-3 positive reaction in LV from 8 out of 19 cases. Among the other histological subtypes, a positive VEGFR-3 reaction was noted in malignant cells from two cases of transitional and one case of pleomorphic MM. Malignant cells from two out of three biphasic and one out of three sarcomatoid MM were also positive for VEGFR-3. Interestingly, one case of the multicystic subtype was negative for VEGFR-3 in malignant cells and faintly positive in an occasional LV. All cases of metastatic carcinoma were negative for VEGFR-3 in the neoplastic cells. In conclusion, VEGFR-3 was expressed in malignant cells from different subtypes of MM, reinforcing the putative role of this marker as a potential therapeutic target in this group of neoplasia. Diagn. Cytopathol. 2007;35:786–791. © 2007 Wiley-Liss, Inc. | en_US |
dc.format.extent | 297762 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pathology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Cytopathology, University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationother | Life and Health Sciences Research Institute, Health Sciences School, University of Minho, Braga, Portugal ; Pathology Division, Adolfo Lutz Institute, SÃo Paulo, Brazil | en_US |
dc.contributor.affiliationother | Life and Health Sciences Research Institute, Health Sciences School, University of Minho, Braga, Portugal | en_US |
dc.contributor.affiliationother | Department of Pathology, Norwegian American Hospital, Chicago, Illinois | en_US |
dc.contributor.affiliationother | Department of Pathology, University of Porto, Porto, Portugal ; IPATIMUP – Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal ; IPATIMUP, Rua Roberto Frias s/n, 4200 Porto, Portugal | en_US |
dc.identifier.pmid | 18008346 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/57412/1/20767_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/dc.20767 | en_US |
dc.identifier.source | Diagnostic Cytopathology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.